Context Heart failure is responsible for morbidity and death. Prognosis is then crucial to assess simply and accurately for guidance of medical care and follow-up. The proSCANNED score has been conceived in order to assess quickly and easily the prognosis of patients. It is crucial to validate this score in a validation cohort, in order to support this new tool for today's clinical practice.

To assess the performance of the pronostic score of heart failure proSCANNED in a two-centre validation sample.

Huit independent predictor variables were identified to build the integer score: Nt-proBNP>5000pg/mL, current smoker, chronic obstructive pulmonary disease, age≥75 years-old, no beta-blockers, dyspnea graded as class III or IV of NYHA scale, left-ventricular ejection fraction≤35%, diabetes. Patients with HF and followed in the Montpellier and Toulouse University Hospitals have been included. The proSCANNED risk score was calculated to predict mortality at one year for each patient.

Two hundreds and seventy-four patients have been included in the validation cohort. The median follow-up was of 23 months. The score of mortality risk has been calculated on 226 patients (82%) of the validation sample, due to some missing data. This score can predict survival at one year with a good discrimination with an AUC at 0,71 (IC 95%: 0.64–0.79) in the validation sample, a good stability (score with an AUC at 0,79 (IC 95% (0,7; 0,89)) in the derivation sample) and a good calibration except for higher risk patients, due to the limited number of high risk patients in the validation cohort.

The proSCANNED score is a new tool of easy use in clinical practice, with a good discrimination, a good stability, and a calibration sufficient to improve the medical care of patients. Other studies would be necessary (1) to assess the score on a larger panel of population, (2) to assess the impact of the use of this score in the medical care of patients.